UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008161
Receipt number R000009610
Scientific Title The study for the efficacy of the combine therapy with proton pump inhibitor and irsogladine for the post-endoscopic submucosal dissection (ESD) gastric ulcer
Date of disclosure of the study information 2012/06/13
Last modified on 2023/12/27 17:29:22

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The study for the efficacy of the combine therapy with proton pump inhibitor and irsogladine for the post-endoscopic submucosal dissection (ESD) gastric ulcer

Acronym

The combined therapy with proton pump inhibitor and irsogladine for post-ESD gastric ulcer

Scientific Title

The study for the efficacy of the combine therapy with proton pump inhibitor and irsogladine for the post-endoscopic submucosal dissection (ESD) gastric ulcer

Scientific Title:Acronym

The combined therapy with proton pump inhibitor and irsogladine for post-ESD gastric ulcer

Region

Japan


Condition

Condition

Gastric ulcer

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To clarify the efficacy of the combined therapy with proton pump inhibitor and irsogladine for the artificial gastric ulcer after endoscopic submucosal dissection

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Cure rates of gastric ulcer at 4 and 8 weeks of the treatment

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Cluster

Blinding

Single blind -investigator(s) and assessor(s) are blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Rabeprazole 10mg/day for 8 weeks p.o.

Interventions/Control_2

Rabeprazole 10mg/day and Irsogladine 4mg/day p.o. for 8 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients over the age of 20 with gastric adenoma or early cancer who were referred to our hospital for the purpose of ESD

Key exclusion criteria

1)Patients with repeated bleeding
2)major organ failure (such as cardiac and
pulmonary complications)
3)Those with drug allergy
4)Concomitant administration of anticoagulants and antiinflammatory
drugs
5)Patients with residual cancer histologically

Target sample size

110


Research contact person

Name of lead principal investigator

1st name Hidemi
Middle name
Last name Goto

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

4668550

Address

65,Tsurumai-cho,Showa-ku,Nagoya

TEL

0527412111

Email

myhr@med.nagoya-u.ac.jp


Public contact

Name of contact person

1st name Ryoji
Middle name
Last name Miyahara

Organization

Nagoya University Graduate School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

470-1192

Address

65,Tsurumai-cho,Showa-ku,Nagoya 466-8560

TEL

09058771669

Homepage URL


Email

ryoji.miyahara@fujita-hu.ac.jp


Sponsor or person

Institute

Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagoya University Hospital Institutional review board

Address

65,Tsurumai-cho,Showa-ku,Nagoya 466-8560

Tel

052-741-2111

Email

sentanjimu@med.nagoya-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2012 Year 06 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

40

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events

none

Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 10 Month 28 Day

Date of IRB

2010 Year 10 Month 28 Day

Anticipated trial start date

2010 Year 10 Month 01 Day

Last follow-up date

2023 Year 12 Month 27 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 06 Month 13 Day

Last modified on

2023 Year 12 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009610


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name